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Plexin B1 Suppresses c-Met in Melanoma: A Role for
Plexin B1 as a Tumor-Suppressor Protein through
Regulation of c-Met
Laurel Stevens1, Lindy McClelland1, Alex Fricke1, Magali Williamson2, IHsin Kuo1 and Glynis Scott3
Melanoma arises through complex genetic and epigenetic changes, resulting in uncontrolled proliferation,
invasion, and metastatic disease. Semaphorins regulate axon guidance through interaction with their receptors,
plexins and neuropilins. Plexin B1, the semaphorin 4D receptor, activates oncogenic receptors c-Met and ErbB-2
in several cell types, suggesting it promotes tumor growth through stimulation of these receptors. A study by
Argast et al. has shown that plexin B1 is a tumor-suppressor protein for melanoma metastasis in a mouse model.
In this report, we show that plexin B1 is lost in metastatic and deeply invasive melanoma in patient samples
in vivo. Unexpectedly, introduction of plexin B1 into human melanoma cell lines suppressed, rather than
activated, the oncogenic receptor, c-Met, by its ligand hepatocyte growth factor (HGF). Plexin B1 also activated
Akt in melanoma. Plexin B1 significantly abrogated cell migration in response to HGF but rendered cells
resistant to apoptosis by cisplatin. Plexin B1 is predicted to function as a classic tumor-suppressor protein in
melanoma, in part through suppression of c-Met signaling and c-Met-dependent migration. However, because
plexin B1 activates Akt, a multifunctional protein involved in tumor progression in several cancers, plexin B1
may function as a tumor promoter in melanomas not driven by c-Met activation.
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INTRODUCTION
Plexins are transmembrane receptors for a class of proteins
called semaphorins, which are membrane-bound and
secreted proteins that were originally identified as neuronal
pathfinding molecules (Artigiani et al., 1999; Tamagnone
and Comoglio, 2004). Since the original identification of
plexins and semaphorins in the nervous system, it is now
recognized that these proteins are widely expressed and
exert diverse biological functions on a variety of cellular
functions including cell migration, cell survival, blood vessel
formation, immune modulation, and tissue patterning. Plexin
receptors are grouped into four families (A–D), and belong
to the c-Met family of scatter factor receptors, on the basis
of a conserved 500 amino acid ‘‘Sema domain’’ that is
present in the extracellular region of plexin and c-Met
receptors (Negishi et al., 2005a). Although the cytoplasmic
region of plexin receptors lacks catalytic activity, numerous
studies show that plexins interact with a variety of small
G proteins that control downstream effects, including
migration, survival, and adhesion (Pasterkamp, 2005; Negishi
et al., 2005b; Puschel, 2007). A role for plexins and
semaphorins in tumor progression, through effects on blood
vessel formation, tumor migration, or survival, has been
identified (Neufeld et al., 2005, 2007; Bagri et al., 2009;
Potiron et al., 2009), and mutations in several plexin
receptors have been identified in human cancers (Balakrishnan
et al., 2009).
Plexin B1 is the receptor for semaphorin 4D (Sema4D),
and transduces signals that lead to growth cone collapse in
hippocampal neurons (Ito et al., 2006). A role for plexin B1
in tumorogenesis has been established in several tumor
types, including breast and prostate cancer (Rody et al.,
2007, 2009; Wong et al., 2007; Argast et al., 2009). A recent
report shows that mitogen-activated protein kinase signaling
downregulates plexin B1 expression in melanoma, and that
introduction of plexin B1 suppresses melanoma metastasis
in a murine model, consistent with a role for plexin B1 as a
tumor-suppressor protein (Argast et al., 2009). Interest has
focused on the plexin B1 receptor because of its reported
association with, and activation of, oncogenic receptors
c-Met and ErbB-2 (Giordano et al., 2002; Conrotto et al.,
2004, 2005; Swiercz et al., 2007). Aberrant c-Met receptor
signaling is implicated in the progression of many tumor
types, including melanoma (Giordano et al., 1992; Maggiora
et al., 1997).
Melanoma is a deadly tumor that arises from normal
human melanocytes, or from melanocyte stem cells.
Melanoma progresses in stages, from in situ tumors, which
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are curable with local excision, to minimally invasive tumors
(‘‘thin’’ melanomas o1mm thick) to deeply invasive tumors
(‘‘thick melanomas’’, 44mm thick) to metastatic disease,
and prognosis is closely correlated with depth of invasion
(Balch et al., 1980; Patrick et al., 2007). In this report, we
examined plexin B1 expression in a large panel of benign and
malignant melanocytic lesions in vivo, and analyzed how
plexin B1 affects c-Met receptor and Akt activation. Our data
indicate that plexin B1 is significantly diminished in
metastatic melanoma and deeply invasive melanomas
in vivo. Introduction of plexin B1 into melanoma cell lines
profoundly suppressed c-Met activation in response to
hepatocyte growth factor (HGF), and suppressed cell migra-
tion in response to HGF, but, paradoxically, also rendered
cells resistant to cisplatin-induced apoptosis and activated
Akt. These data suggest that the mechanism by which plexin
B1 functions as a tumor-suppressor protein for melanoma is,
in part, through inhibition of c-Met activity. However, the net
effect of loss of plexin B1 on melanoma progression is likely
to be complex, and will depend on relative levels of c-Met
suppression and plexin B1-dependent Akt activation.
RESULTS
Plexin B1 receptor is lost at the protein and message level in
human melanoma
Total cell lysates of normal human melanocytes and of six
human melanoma cell lines were blotted for plexin B1
(Figure 1a). Melanocytes expressed plexin B1, whereas none
of the melanoma cell lines, with the exception of WM165,
expressed detectable plexin B1. The WM165 melanoma cell
line showed faint yet detectable plexin B1 protein. Real-time
PCR (Figure 1b) showed that loss of plexin B1 expression
occurred at the transcriptional level in melanoma cell lines.
TheWM165 melanoma cell line expressed mRNA for plexin B1,
but less than half of the amount present in normal melanocytes.
None of the six human melanoma cell lines, or normal human
melanocytes, expressed detectable Sema4D, as shown by
western blotting (Figure 1c). Purified recombinant Sema4D was
used as a positive control (see Supplementary Figure S1 online).
Plexin B1 expression is significantly decreased in metastatic
melanoma and in deeply invasive primary melanomas
To determine whether plexin B1 expression is lost during
melanoma progression in vivo, we investigated plexin B1
expression in melanocytic lesions using tissue microarrays
(TMA) of nevi (n¼26), primary melanoma (n¼ 27), and
metastatic melanoma (n¼24; Figure 2a and b). Plexin B1
was expressed in virtually all nevi, with strong cytoplasmic
and membraneous staining identified within nevic cells.
Primary melanomas showed a more heterogeneous pattern of
plexin B1 expression, with thin melanomas expressing more
plexin B1 than thicker melanomas (Figure 2c and d).
Metastatic melanomas showed a marked loss of plexin B1
expression; a statistically significant (P¼0.028) decrease in
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Figure 1. Plexin B1 is lost at the transcriptional level in melanoma. (a) Total cell lysates of melanocytes (MC) and six human melanoma cell lines were
blotted with antibodies to plexin B1. Melanocytes express plexin B1 (50 mg loaded). Plexin B1 receptor is completely absent in all melanoma cell lines,
with the exception of WM165, which shows a faint band (arrowhead). Primary melanomas are indicated with an asterisk. (b) mRNA was reverse transcribed
from melanocytes and from six human melanoma cell lines. Quantitative real-time PCR of each sample was performed in triplicate against a standard curve of
plexin B1 PCR product to arrive at a quantitative plexin B1 level. Five of the six cell lines either had absent or barely detectable plexin B1 mRNA compared with
melanocytes. There was detectable plexin B1 message in WM165 cells, but much less than in melanocytes, consistent with the lower plexin B1 protein
expressed in WM165 cells. Primary melanomas are indicated with an *. Results are the averaged amount of plexin B1 message of three separate experiments
(±SD). (c) Representative western blot of lysates of normal human melanocytes and of six human melanoma cell lines, resolved on 10% SDS-PAGE, and
blotted for Sema4D. Purified recombinant Sema4D (see Supplementary Figure S1 online) was used as a control. None of the cells express detectable Sema4D.
Primary melanomas are indicated with an asterisk.
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plexin B1 expression was observed in subjects with meta-
static melanoma compared with nevi and primary melano-
ma. However, not all metastatic melanomas lost plexin B1
expression, with retention of plexin B1 noted in a subset of
cases. Endothelial cells in cutaneous blood vessels also
expressed plexin B1 (Figure 2e).
Although the averaged intensity staining for plexin B1
expression was essentially identical in nevi and primary
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Figure 2. Plexin B1 is expressed in benign nevi and in primary melanoma, but is diminished in deeply invasive and metastatic melanomas. (a) Representative
images of cores from TMA of nevi, primary melanoma (Mel), and metastatic melanoma (MM, subjects 10 and 22) stained for plexin B1. Nevic cells are
nested and strongly express plexin B1. A core from a subject with primary melanoma (depth 1.2mm) is shown, in which melanoma cells strongly express
plexin B1 (arrowheads). Cores from two different subjects with metastatic melanoma, stained for plexin B1, are shown. The metastatic tumor from subject 10
has completely lost expression of plexin B1; in contrast, the metastatic melanoma from subject 22 has retained strong expression of plexin B1. Bar¼ 100mM.
(b) Shown is the averaged intensity score (IS) for plexin B1 staining from all cases of nevi, primary melanoma, and metastatic melanoma,±SD. The averaged IS
of plexin B1 staining is significantly (P¼0.028) lower in metastatic melanoma, compared with nevi and primary melanoma. (c) Shown is the averaged intensity
score (IS) of primary melanomas by Breslow depth. When cases of primary melanoma were separated into groups of different Breslow depths, a clear trend
of decreasing plexin B1 expression with increasing depth of invasion is present, although results did not achieve statistical significance. Melanomas with
a depth between 0 and 2mm had a plexin B1 IS comparable to that of benign nevi, whereas thicker melanomas (44mm) expressed plexin B1 at levels
comparable to that of metastatic melanomas. (d) Representative images of cores from TMA of primary melanoma from a subject with a Breslow depth of 2mm,
and from a subject with a primary melanoma of Breslow depth 4.3mm, stained for plexin B1. Strong plexin B1 expression is present in the thin melanoma,
whereas there is complete loss of plexin B1 expression in the thicker melanoma. Bar¼400 mM. (e) Examination of plexin B1 in stained TMA revealed strong
expression of plexin B1 in endothelial cells of blood vessels (arrows; bar¼20 mM).
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melanoma (5.4 and 5.6, respectively), when primary mela-
nomas were divided into groups on the basis of Breslow
depth, a clear trend of decreased plexin B1 expression with
increasing depth of invasion was noted (Figure 2c and d).
Figure 2d shows representative images of a melanoma of
Breslow depth 2.0mm, which exhibits strong plexin B1
expression; a representative image of a deep or ‘‘thick’’
melanoma (Breslow depth 4.3mm) is shown in which plexin
B1 expression is absent. The intensity staining of plexin B1 in
melanomas of 44mm was comparable with that of meta-
static melanomas (intensity staining 2.8 and 3.3, respec-
tively). These data suggest that loss of plexin B1 expression is
a relatively late event in melanoma progression, and may
facilitate melanoma invasion or metastasis.
Plexin B1 inhibits HGF-dependent c-Met activation and
migration
Activation of c-Met signaling is implicated in the progression
of a variety of tumors, including melanoma (Otsuka et al.,
1998; Birchmeier et al., 2003). Plexin B1 signaling activates
c-Met in epithelial and endothelial cell lines (Giordano et al.,
2002; Conrotto et al., 2004, 2005), as well as in the vascular
endothelium (Conrotto et al., 2005), resulting in angiogen-
esis. To determine whether plexin B1 regulates c-Met activity
in melanoma, we established plexin B1 in YUSIK human
metastatic melanoma cell lines, using lentiviral vectors.
Western blotting with antibodies against plexin B1 revealed
a predominant band of 100 kDa, which was weak or absent
in LacZ-expressing clones, consistent with expression of
plexin B1 (Supplementary Figure S2A). BrdU uptake assays
confirmed that introduction of plexin B1 suppresses prolif-
eration of melanoma in a ligand-independent manner,
consistent with previous reports (Supplementary Figure S2B;
Argast et al., 2009). Introduction of plexin B1 into the human
melanoma cell line YUMAC also resulted in a suppression of
proliferation (data not shown).
To determine whether plexin B1 signaling stimulates
c-Met receptor activation, serum-starved cells were treated
with Sema4D (100 ngml–1) for 10 or 30 minutes, followed
by analysis of phosphorylated c-Met by western blotting
(Figure 3a). Although our data indicate that plexin B1 is
constitutively active in melanoma clones, we tested the
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Figure 3. Plexin B1 suppresses c-Met activation and migration in melanoma. (a) Plexin B1-expressing cells (PBA) were serum starved for 24 hours and
then treated with Sema4D (S4D; 100 ngml–1) for 10 or 30 minutes. Controls consisted of cells treated with heat-inactivated Sema4D (HI S4D) for 30 minutes.
Total cell lysates (60 mg) were resolved on 10% SDS-PAGE and blotted for phosphorylated c-Met and total c-Met. Positive controls consisted of LacZ-expressing
cells treated with HGF (10 ngml–1) for 10 minutes. Sema4D did not induce c-Met phosphorylation. Results are representative of four separate experiments.
(b) Cells were serum-starved overnight and then treated with HGF (10 ngml–1) for 10 or 30 minutes. Controls consisted of untreated cells (‘‘NT’’). Total cell
lysates were resolved on 10% SDS-PAGE and blotted for P-c-Met, total-c-Met, and b-actin. In the absence of HGF, c-Met receptor was not phosphorylated in
either LacZ or PBA cells. Treatment with HGF stimulated robust c-Met phosphorylation in LacZ cells. In contrast, PBA cells showed barely detectable c-Met
phosphorylation in response to HGF (arrows). Results are representative of five separate experiments. (c) Cells were serum staved and treated with HGF as
described above. Total cell lysates were resolved on 10% SDS-PAGE and blotted for P-c-Met, P-Gab1, total Gab, and b-actin. HGF-induced activation of c-Met
and the adapter protein Gab1 in LacZ cells. As expected, PBA cells showed little detectable c-Met phosphorylation in response to HGF, and also showed
diminished Gab1 phosphorylation (arrows). Results are representative of two separate experiments. (d) HGF-stimulated migration of LacZ cells, but not
of plexin-B1-expressing cells. LacZ (gray bars) and PBA cells (black bars) show similar rates of migration in the presence of vehicle (V). In the presence
of low doses of HGF (10 ngml–1), migration was stimulated in LacZ cells (1.7-fold), but not in plexin B1-expressing cells. At higher doses (50 ngml–1),
HGF stimulated a 2.3-fold increase in migration in LacZ cells. In contrast, HGF at this dose did not stimulate migration in PBA cells. Differences in migration
of LacZ and PBA cells, in response to HGF (50 ngml–1), were highly significant (P¼ 0.0081).
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effects of Sema4D on c-Met activity to unmask potential
ligand-dependent signaling to the c-Met receptor. Controls
consisted of cells treated with heat-inactivated Sema4D.
Sema4D did not stimulate phosphorylation of the c-Met
receptor, even when cells were exposed to high doses of
Sema4D (up to 200 ngml–1) for up to 4 hours (data not
shown). To determine whether plexin B1 inhibits c-Met
receptor activation, we analyzed levels of phosphorylated
c-Met in LacZ and plexin B1-expressing cells in response to
the c-Met ligand, HGF (Figure 3b). HGF (10 ngml–1) induced
robust phosphorylation of the c-Met receptor in LacZ cells. In
contrast, c-Met phosphorylation in response to HGF was
markedly decreased in plexin B1-expressing cells at 10 and
30 minutes. The percentage decrease in HGF-dependent
c-Met phosphorylation ranged from 12.9 to 54% (Table 1).
Abrogation of c-Met phosphorylation in a second melanoma
cell line (YUMAC), engineered to express plexin B1, was also
observed (Supplementary Figure S3). The Gabl protein is a
multisystem docking protein that is recruited to the c-Met
receptor, and phosphorylated on c-Met receptor activation
(Bertotti and Comoglio, 2003). Treatment of LacZ cells with
HGF (10 ngml–1) stimulated c-Met and Gab1 phosphoryla-
tion. Gab1 phosphorylation in response to HGF was
markedly diminished in cells expressing plexin B1, and
correlated with levels of c-Met phosphorylation (Figure 3c).
A hallmark of c-Met activation is stimulation of cell
migration and invasion (Bardelli and Comoglio, 1997). To
determine whether plexin B1 suppresses migration in
response to HGF, cells in basal medium were placed in the
top well of a migration chamber, and HGF (10 or 50 ngml–1)
was placed in the bottom wells. Cells were allowed to
migrate for 24 hours and migration was quantified by
florescence labeling of migrated cells, as per manufacturer’s
instructions (Figure 3d). A dose-dependent increase in
migration of LacZ cells in response to HGF was observed.
In contrast, HGF failed to stimulate migration in plexin
B1-expressing cells. Differences in migration between LacZ
and plexin B1-expressing cells in response to HGF
(50 ngml–1) were highly significant (P¼0.0081).
Plexin B1 activates Akt in melanoma
Akt is frequently activated in malignant cells, resulting in a
variety of downstream effects, including resistance to
apoptosis, and is activated in metastatic melanoma (Dai
et al., 2005; Tokunaga et al., 2008). To determine whether
plexin B1 regulates Akt activation in melanoma, serum-
starved LacZ- and plexin B1-expressing cells were blotted for
phospho-Akt (Figure 4a). Robust phosphorylation of Akt was
detected in plexin B1-expressing cells, but not in LacZ
controls. To determine whether Akt suppresses apoptosis in
plexin B1-expressing cells, cells were treated with the
specific PI3-kinase inhibitor LY294002, and levels of
activated caspase-3 were measured by FACS analysis
(Figure 4b). LY294002 increased levels of activated cas-
pase-3 expression in plexin B1-expressing cells, indicating
that plexin B1 suppresses apoptosis through PI3-kinase-Akt
activation. As expected, inhibition of Akt had little effect on
levels of caspase-3 in LacZ cells, because of low levels of
active Akt in these cells (Figure 4a).
Akt is a downstream target of c-Met signaling (Puri et al.,
2007; Ye et al., 2008). To determine whether plexin B1
abrogates HGF-dependent activation of Akt, serum-starved
cells were treated with HGF, and lysates were blotted for
phospho-Akt (Figure 4c). As expected, under basal condi-
tions, Akt was phosphorylated in plexin B1-expressing cells,
but not in LacZ controls. After treatment with HGF, robust
phosphorylation of Akt was detected in LacZ cells, and
was similar to levels of Akt phosphorylation in plexin
B1-expressing cells. These data indicate that suppression of
c-Met activation by plexin B1 is not sufficient to decrease
HGF-dependent Akt activation.
Plexin B1 renders melanoma relatively resistant to
cisplatin-induced apoptosis
Cisplatin is a platinum chemotherapeutic agent that is used to
treat patients with metastatic melanoma (Barabas et al.,
2008). Our data indicate that plexin B1 activates Akt, and that
inhibition of Akt increases active caspase-3 expression in
plexin B1-expressing cells (Figure 4a and b). To determine the
effect of plexin B1 on cisplatin-induced apoptosis in
melanoma, cells were treated with cisplatin (7 mM) for 48
hours and active caspase-3 was analyzed by FACS analysis.
LacZ- and plexin B1-expressing cells had low levels of active
caspase-3 in the absence of cisplatin (o2%, data not shown).
Plexin B1 rendered melanoma cells relatively resistant to
cisplatin-induced apoptosis compared with LacZ controls
(Figure 5 and Table 2). Active caspase-3 expression in plexin
B1-expressing cells ranged from 3.6 to 25.2% after treatment
with cisplatin. In contrast, active caspase-3 expression in
cisplatin-treated LacZ cells ranged from 12.2 to 57.5%.
DISCUSSION
Plexin B1 interacts with a variety of small G proteins to
regulate cell migration, proliferation, and apoptosis. Loss of
plexin B1 expression in vivo has been documented in breast
cancer and renal cell carcinoma, and a recent report has
shown that introduction of plexin B1 into melanoma cell
lines suppresses tumor formation in mice, consistent with a
role for plexin B1 as a tumor-suppressor protein in melanoma
(Rody et al., 2007, 2009; Gomez Roman et al., 2008; Argast
et al., 2009). Analysis of TMAs of nevi, primary melanoma,
Table 1. P-c-Met/Met in response to HGF in
melanoma cells expressing plexin B1, compared with
LacZ controls1
Exp. 1 Exp. 2 Exp. 3
Treatment time
(HGF) LacZ PBA %k LacZ PBA %k LacZ PBA %k
100 2.38 1.79 25.0 0.92 0.64 29.9 1.13 0.56 50.4
300 2.25 1.51 32.7 0.83 0.73 12.9 1.24 0.56 54.6
Abbreviation: HGF, hepatocyte growth factor.
1Results of three experiments are shown. Numbers represent arbitrary
units from densitometry scans. The % decrease represents the decrease in
phosphorylated c-Met in PBA cells compared with LacZ cells (normalized
to actin) in response to HGF.
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and metastatic melanoma indicates significant loss of
plexin B1 in metastatic melanomas in vivo. Nevi and thin
melanomas generally showed strong expression of plexin
B1, with loss of plexin B1 in deeply invasive and metastatic
tumors, suggesting that loss of plexin B1 may contribute to
later stages of tumor progression, including invasion and
metastasis. As plexin C1 is also lost in metastatic melanoma
(Scott et al., 2008), it is interesting to speculate that loss of
both receptors may have a synergistic effect in promoting
melanoma metastasis. When introduced into two human
melanoma cell lines, plexin B1 significantly suppressed
melanoma proliferation through signaling pathways yet to
be defined. As our data show that plexin B1 activates Akt, our
ability to propagate plexin B1-expressing clones may be
partly because of Akt activation, which suppresses apoptosis
and would counteract signaling that suppresses proliferation.
The plexin B1 ligand, Sema4D, did not affect cellular
function in plexin B1-expressing cells, consistent with
ligand-independent signaling of the receptor as previously
reported (Giordano et al., 2002; Conrotto et al., 2004). This
effect may be due to proteolytic processing of an inhibitory
portion of the extracellar domain of the receptor by subtilisin-
like proprotein convertases, which results in enhanced
sensitivity to ligand (Artigiani et al., 2003).
c-Met receptor activation, either through activating muta-
tions in the receptor or through autocrine production of the
c-Met ligand HGF, stimulates the progression of a wide
variety of tumors, including melanoma. We observed
suppression of c-Met activation in two human melanoma
cell lines (YUSIK and YUMAC) genetically engineered to
express the plexin B1 receptor. We were surprised to find that
plexin B1 abrogates c-Met phosphorylation in response to
HGF in melanoma, because previous reports show that
plexin B1 stimulates the activity of c-Met (Giordano et al.,
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Figure 4. Plexin B1 activates Akt in melanoma. (a) Cells were serum starved for 24 hours, lysed, and resolved on 10% SPS-PAGE, and blotted for phospho-Akt,
total Akt, and b-actin. Phosphorylation of Akt is seen in cells expressing plexin B1 (PBA) but not in LacZ cells. Results are representative of six separate
experiments. (b) Cells in basal media were treated with the PI3-kinase inhibitor LY2940002 (‘‘I’’; 50 mM) or with vehicle (‘‘V’’: DMSO) for 48 hours, and
active caspase-3 was quantified by flow cytometry. Treatment of LacZ cells with LY2940002 had minimal effect on active caspase-3 expression. In contrast,
inhibition of PI3-kinase increased active caspase-3 by 23% in PBA cells. Results are representative of three separate experiments. (c) Cells were starved overnight
in basal medium and then treated with HGF (10 ngml–1) for 10 or 30 minutes. Total cell lysates were resolved on 10% SDS-PAGE and blotted for P-Akt and
total Akt. Under basal conditions (‘‘NT’’), Akt is phosphorylated in PBA, but not in LacZ control cells (arrows). No difference was noted in the levels of
P-Akt in LacZ and PBA cells treated with HGF. Results are representative of three separate experiments.
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2002; Conrotto et al., 2004; Swiercz et al., 2007). These data
point to a previously unrecognized role for plexin B1 in
suppression of c-Met activity. Data showing that plexin B1
suppresses c-Met-dependent migration suggest a potential
mechanism by which plexin B1 functions as a tumor-
suppressor protein for melanoma. Further studies will be
needed to determine whether plexin B1 suppresses other
c-Met-dependent functions in melanoma, including prolif-
eration and apoptosis. It is unclear why plexin B1 inhibits
c-Met receptor activation in melanoma, in contrast to its
stimulatory effects reported in other cell types. A potential
explanation is competitive inhibition of the HGF binding
domain by plexin B1. HGF binds to the Sema domain of the
c-Met receptor (Gherardi et al., 2003; Kirchhofer et al., 2004;
Kong-Beltran et al., 2004). The c-Met receptor dimerizes, and
dimerization requires the Sema domain, which is highly
homologous with the Sema domain of plexin B1 (Kong-
Beltran et al., 2004). Plexin B1 may dimerize with the c-Met
receptor through their Sema domains, resulting in decreased
affinity of c-Met for HGF.
Our results show that plexin B1 activates the PI3-kinase-
Akt pathway. Treatment of cells with cisplatin, a chemother-
apeutic agent that stimulates apoptosis, showed that plexin
B1 renders melanoma cells relatively resistant to apoptosis.
The PI3-kinase-Akt pathway controls several aspects of
cellular function, including migration, proliferation, and
apoptosis (Tokunaga et al., 2008). The fact that plexin B1
activates Akt suggests a likely mechanism by which plexin
B1-expressing melanoma cells are resistant to apoptosis in
response to cisplatin, and may counterbalance the inhibitory
effects of plexin B1 on cell proliferation. Although we
observed a significant loss of plexin B1 expression in
metastatic melanoma in vivo, some cases of metastatic
melanoma retained strong expression of plexin B1. It is
possible that this subset of metastatic melanoma may be
more resistant to chemotherapeutic agents that induce
apoptosis, compared with metastatic tumors that have lost
plexin B1 expression. Further experiments will be necessary
to test this notion.
The final effect of plexin B1 on melanoma progression is
likely to depend on the balance between c-Met receptor
blockade and signaling of the plexin B1 receptor to down-
stream targets that are independent of c-Met signaling, such
as Akt (Figure 6). As the majority of metastatic melanomas
in vivo show upregulation of c-Met expression (Natali et al.,
1993), and because autocrine or paracrine stimulation of the
c-Met receptor drives melanoma metastasis (Otsuka et al.,
1998), loss of plexin B1 would be expected to promote tumor
progression through release of inhibition of c-Met signaling,
resulting in decreased migration, acting as a classic tumor-
suppressor protein. However, our data also show that plexin
B1 renders melanoma cells relatively resistant to apoptosis,
and activates Akt, suggesting that plexin B1 may promote
melanoma progression by rendering cells resistant to
chemotherapy. In the subset of tumors that are not driven
through c-Met activation, plexin B1 may function as a tumor
promoter by rendering cells resistant to apoptosis.
MATERIALS AND METHODS
Reagents
Rabbit polyclonal antibodies to b-actin, mouse monoclonal anti-
bodies to plexin B1, rabbit polyclonal antibodies to CD100/Sema4D,
and rabbit polyclonal antibodies to c-Met were purchased from
Santa Cruz Biotechnologies (Santa Cruz, CA). Rabbit monoclonal
antibody to phospho-Met, phospho-AKT, phospho-Gab1, and total
AKT and Gab1 were purchased from Cell Signaling Technology
(Beverly, MA); horseradish peroxidase-conjugated goat anti-rabbit
and goat anti-mouse antibodies were purchased from Sigma,
(St Louis, MO). Mouse IgG2 and HGF were purchased from Sigma.
Plexin B1 renders melanoma cells resistant to apoptosis:
active caspase-3 expression in cells treated with cis-platin
PBA + CP LacZ + CP
P2
1.000
750
500
250
0
102 103 104 105
Blue D 610/20–A
Co
un
t
Figure 5. Plexin B1 suppresses cisplatin-induced apoptosis. Cells in complete
media were treated with 7 mM cisplatin for 48 hours before being stained for
active caspase-3 and analyzed by flow cytometry. Shown is a representative
graph showing the LacZ peak shifted to the right, indicating more active
caspase-3 labeling compared with PBA cells. Results are representative of
three separate experiments.
Table 2. Active caspase-3 expression in response to
cis-platin in LacZ and PBA cells1
Cell type % Active caspase-3 Fold decrease
Exp1
LacZ 38.2 —
PBA 3.6 10.61
Exp2
LacZ 12.2 —
PBA 5.2 2.35
Exp3
LacZ 57.5 —
PBA 25.2 2.28
1Results of three experiments are shown. Numbers represent the
percentage of cells expressing active caspase-3. The fold decrease
represents the decrease in active caspase-3 in PBA cells compared with
LacZ cells, in response to cis-platin, for each experiment.
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The active caspase-3 apoptosis kit was purchased from BD
Biosciences Pharmingen (San Diego, CA). Cisplatin was purchased
from Alexis Biochemicals (San Diego, CA); LY2940002 was
purchased from Cell Signaling Technology; full-range rainbow
molecular weight marker was purchased from Amersham Life
Sciences (Arlington Heights, IL).
Cells and cell culture
The YUSIK melanoma cell line (Yale Skin Disease Research Core
Center, New Haven, CT) was maintained in OptiMEM (Gibco,
Carlsbad, CA) with 5% fetal bovine serum (HyClone, Logan, UT).
Stable transfectants were maintained in OptiMEM with 5% fetal
bovine serum and blasticidin (Invitrogen, Carlsbad, CA) at 2mgml–1.
Neonatal foreskins were obtained according to the University of
Rochester Research Subjects Review Board guidelines and were
the source of cultured human melanocytes and were cultured as
previously described (Scott et al., 2008).
Recombinant Sema4D-Fc
Recombinant human Sema4D was kindly provided by Hitoshi
Kikutani (Osaka University, Osaka, Japan). The protein was
expressed as an Fc-tagged protein in pEFBos vector and was purified
from conditioned medium of COS-1 cells on protein A Sepharose
CL-4B beads as described (Ishida et al., 2003). Protein purity was
assessed by silver staining of gels (Supplementary Figure S1).
Lentiviral transduction
Full-length plexin B1 cDNA was kindly provided by Dr Alan Hall
(Memorial Sloan Kettering Cancer Center, New York, NY) and was
cloned into pLenti6/V5-D-TOPO, tagged at its carboxyl terminal
with the vesicular stomatitis virus (VSV) tag, and its sequence
was verified. Virus, produced in 293FT cells, was transduced into
YUSIK melanoma cells with polybrene (8 mgml–1). Infected cells
were selected with blasticidin, and cloning rings were used to isolate
clones. Plexin B1 expression was confirmed by western blotting in
several clones, and the clone with the most abundant expression
(‘‘PBA’’) was used (Supplementary Figure S2). Melanocytes, used as
positive controls, showed bands at 250, 100, and 45 kDa, consistent
with reports showing that plexin B1 is cleaved by pro-protein
convertases (Artigiani et al., 2003).
Construction, staining, and analysis of TMAs
The project received Institutional Review Board exemption from the
Human Subjects Review Board at the University of Rochester:
Category 4 (45 CRF 46.101): secondary use of preexisting data. A
total of 26 cases of benign nevi, 27 cases of melanoma primary to the
skin, and 24 cases of metastatic melanoma were chosen from
formalin-fixed, paraffin-embedded archival material from the Strong
Memorial Department of Pathology. One of the authors (GS)
diagnosed each case during clinical duties as Director of Dermato-
pathology at the Strong Memorial Hospital, Rochester, NY. The
slides from each case were reexamined and three representative
areas from each slide were chosen. Three 1mm cores corresponding
to these areas were removed from the paraffin block and placed in a
recipient block. All benign nevi were dermal nevi with a minimal
junctional component, primary melanomas had depths of o1mm
(n¼ 9), between 1.01 and 2.0mm (n¼ 8), between 2.01 and 4.0mm
(n¼ 6), and4 4mm (n¼ 4). For metastatic melanoma, 11 out of 24
cases were metastatic to lymph nodes, 5 out of 24 were metastatic to
skin, and 8 out of 24 cases were metastatic to organs including the
gastrointestinal system, lung, and bone.
Staining of TMA for plexin B1
Sections were stained on the Dako AutostainerPlus using the
Dako Flex Plus Kit as per the manufacturer’s instructions (Dako,
Carpenteria, CA). Slides were incubated in Target Retrieval Buffer,
EDTA pH 9.0 (Dako) at 99 1C for 20 minutes. Slides were incubated
with anti-plexin B1 mouse monoclonal antibodies for 30 minutes,
followed by incubation with horseradish peroxidase-conjugated goat
anti-mouse antibodies. The reaction product was developed with
amino-ethyl carbizol and the slides were counterstained in Mayer’s
hematoxylin. Negative controls consisted of mouse IgG (Sigma)
instead of the primary antibody.
Analysis of TMAs
The intensity of staining of each 1mm core was rated on a scale of
0–3, with 0¼ negative; 1¼weak; 2¼moderate; and 3¼ strong. For
all cases, staining, when present, was diffuse, with all nevic cells or
melanoma cells expressing uniform cytoplasmic and membrane
staining for plexin B1. Each core was examined by one of the authors
(GS) and separately scored, and the staining intensity of cores was
Model of the role plexin B1 in melanoma prgression
Melanocytes, nevi, and primary
melanoma
Plexin B1 c-Met
P-Akt c-Met activity and 
migration
P-Akt
c-Met activity and
migration
Plecxin B1 c-Met
Deeply invasive melanoma and metastatic
melanoma
Figure 6. Proposed model of the role of plexin B1 in melanoma progression. In melanocytes, benign nevi, and early melanoma, plexin B1 suppresses
c-Met activity, resulting in suppression of migration. During melanoma progression, plexin B1 expression is lost or diminished, releasing inhibition of c-Met
receptor signaling. This is predicted to result in tumor progression in a c-Met-dependent manner. However, because plexin B1 also activates Akt, it is
predicted that the balance between Akt activity and c-Met inhibition will determine the net effect of the loss of plexin B1 in melanoma progression.
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averaged to arrive at an intensity score. Cores with o50% of
designated tissue were disregarded.
Quantitative real-time PCR
Total RNA was isolated using the RNeasy Mini Kit (QIAgen, Valencia,
CA) according to the manufacturer’s instructions. Reverse transcription
was performed using 0.75 mg of total RNA with SuperScript II
reverse transcriptase (Invitrogen). PCR was performed using iQ SYBR
Green Supermix (BioRad Laboratories, Hercules, CA) on the Applied
Biosystems ABI prism 7700 sequence detection system (BioRad
iCycler, Foster City, CA). Primers used for amplification of plexin B1
were forward: 50-AAGAACCCCAAGCTGATGCTGCGCAGG-30;
reverse: 50-CCTTCACGGGCACGCCCTGGGCCT-30. The conditions
were as follows: 95 1C, 3 minutes (1 cycle); 95 1C, 15 seconds,
54.5 1C, 30 seconds, 72 1C, 40 seconds (40 cycles). Primers used for
amplification of b-actin were forward: 50-CACGCACGATTTCCC
GCTCGG-30; reverse: 50-CAGGCTGTGCTATCCTGTAC-30. The con-
ditions were 94 1C, 3 minutes; 94 1C, 30 seconds, 65 1C, 30 seconds,
72 1C, 90 seconds, 72 1C, 7 minutes (all 30 cycles). The PCR product
was resolved on 1% agarose gels, sequenced, and verified.
Quantification of the PCR product was determined by analyzing a
standard curve of known amounts of plexin B1 PCR product to
unknown samples. Samples were then normalized to b-actin.
BrdU
BrdU uptake was analyzed using a Calbiochem BrdU Cell
Proliferation Assay kit (Los Angeles, CA). Cells (104) were plated
in 96-well tissue culture dishes in basal media and incubated at
37 1C for 4–6 hours before the addition of BrdU. Controls consisting
of cells without BrdU, and blanks with media only, were included.
Cells were incubated overnight and then fixed, and BrdU uptake was
detected according to the manufacturer’s instructions. Absorbance was
measured on a Multiskan Microplate Reader (Finstruments, Vienna,
VA) at 450/540nm. Each experiment was conducted in triplicate wells,
with a total of nine wells analyzed per condition.
Western blotting
Cells were lysed on ice using radioimmunoprecipitation assay buffer
(150mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, 50mM
Tris-HCl) with protease inhibitors (Boehringer Mannheim GmbH,
Mannheim, Germany) and phosphatase inhibitors (GBiosciences,
St Louis, MO). Lysates were resolved on SDS-PAGE and transferred
to nitrocellulose paper. Immunoreactive proteins were visualized
using SuperSignal West Pico Substrate (Pierce Chemical, Rockford, IL).
Densitometry analysis was performed using NIH Image 1.6.3 freeware.
Migration assay
Migration assays were performed using Chemicon QCM Chemotaxis
96-well Fluorometric Cell Migration Assay with 8mm pore size (Billerica,
MA). Cells (5 104) were plated into the top well of the migration
chamber in basal medium and incubated at 37 1C for 24 hours. The
bottom wells contained basal media with vehicle, or basal media with
HGF. Cells were detached from the underside of the migration chamber
plate with detachment solution and lysed and labeled with CyQuant GR
Dye and lysis buffer as described in the kit protocol. Fluorescence
was measured at 490/510–570 nm with a Modulus Microplate
Photometer (Turner Biosciences, Sunnyvale, CA). Each experiment
was conducted in triplicate wells, with a total of nine wells analyzed
per condition. Background florescence (fluorescence of labeled
media, in the absence of cells) was subtracted and differences in
migration were analyzed by Student’s t-test.
FACS analysis for cisplatin-induced active caspase-3
Cells (5 105) were plated in 100mm tissue culture dishes in full
media (Opti-MEMþ 5% fetal bovine serumþ blasticidin). After 48
hours, media were replaced with full media alone or media containing
7mM cisplatin were made fresh for each experiment. After 48 hours,
media containing floating cells were collected, and combined with
adherent cells removed from the dish by trypsinization. Cells were
stained for active caspase-3 with the BD Active Caspase-3 apoptosis kit
as per the manufacturer’s instructions and analyzed by flow cytometry
with an LSR II flow cytometer (BD Biosciences).
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